oncologyTariff appliesAnnex III — Jul 31 2026

Imbruvica Tariff Rate & July 31, 2026 Deadline

Imbruvica (Ibrutinib) — manufactured by AbbVie in Germany. Treats leukemia, lymphoma. Typical US retail $16,800 per month.

Tariff breakdown

Applicable rate: 100% (Annex III)
Effective date: 2026-07-31 (98 days away)
Manufacturer: AbbVie
Country of origin: Germany
Annex III?: Yes
Current monthly retail: $16,800

Projected monthly retail, by pass-through scenario

Scenario	Pass-through	New monthly retail	Annual increase
Conservative	30%	$21,840	+$60,480
Likely	50%	$25,200	+$100,800
Worst case	100%	$33,600	+$201,600

Scenarios based on historical brand-pharma cost-shock pass-through. Not a forecast.

HTS classification

HTS 3004.90.9299

Ibrutinib capsules / tablets, retail packaging, HTS 3004.90. Manufactured in Germany by AbbVie — fully subject to tariff.

Source: USITC Harmonized Tariff Schedule, 2026 Revision 2 — hts.usitc.gov

Alternatives: generics, biosimilars & US-made options

Calquence (acalabrutinib, AstraZeneca)

therapeutic alternative

Second-generation BTK inhibitor, UK/Sweden-made — tariff applies.

Brukinsa (zanubrutinib, BeiGene)

therapeutic alternative

BeiGene is not on Annex III (not among the 17 large pharma). Effective Sept 29, 2026. Partial manufacturing in the US.

Always consult your prescriber before switching medications. Biosimilars and generics are not interchangeable in every state without physician approval.

FAQ: Imbruvica and the 2026 tariff

Will my Imbruvica prescription cost more after July 31, 2026?

Likely yes. Imbruvica is manufactured in Germany and is not exempt. Our conservative-case scenario assumes 30% pass-through (retail +$5,040/month), our likely-case 50% (+$8,400/month), and worst-case full pass-through (+$16,800/month).

Can I switch to a generic version of Ibrutinib?

No FDA-approved generic of Ibrutinib is widely available in the US as of 2026 Q2. Biosimilars or therapeutic alternatives (listed above) are the practical substitutes.

Is Imbruvica on the Medicare negotiated-price list?

Imbruvica is not among the first-round Medicare-negotiated drugs effective 2026. Check CMS announcements for subsequent negotiation rounds.

Importing pharmaceuticals commercially?

This page covers consumer drug pricing. For business imports (including finished-dose pharmaceuticals), use the full US import tariff calculator with HTS classification and Section 301/232/122 breakdown.

Disclaimer: Informational estimates based on public list prices, the April 2, 2026 Proclamation text, and USITC HTS data. Not medical, legal, or financial advice.

Talk to your doctor, pharmacist, and insurer about your specific medication.